StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research report released on Wednesday morning. The brokerage issued a hold rating on the stock.
Separately, HC Wainwright decreased their price target on shares of DBV Technologies from $20.00 to $10.00 and set a buy rating for the company in a research note on Wednesday, May 8th.
View Our Latest Stock Report on DBV Technologies
DBV Technologies Price Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.16. The firm had revenue of $1.41 million for the quarter, compared to analysts’ expectations of $3.20 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. Equities analysts expect that DBV Technologies will post -1.22 earnings per share for the current year.
Hedge Funds Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
- Five stocks we like better than DBV Technologies
- Best Stocks Under $5.00
- Why This AI Stock is Rising Despite Tech Sell-Off
- Technology Stocks Explained: Here’s What to Know About Tech
- MarketBeat Week in Review – 7/15 – 7/19
- What is a Special Dividend?
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.